» Articles » PMID: 22435566

Pathogenetic Importance and Therapeutic Implications of NF-κB in Lymphoid Malignancies

Overview
Journal Immunol Rev
Date 2012 Mar 23
PMID 22435566
Citations 82
Authors
Affiliations
Soon will be listed here.
Abstract

Derangement of the nuclear factor κB (NF-κB) pathway initiates and/or sustains many types of human cancer. B-cell malignancies are particularly affected by oncogenic mutations, translocations, and copy number alterations affecting key components the NF-κB pathway, most likely owing to the pervasive role of this pathway in normal B cells. These genetic aberrations cause tumors to be 'addicted' to NF-κB, which can be exploited therapeutically. Since each subtype of lymphoid cancer utilizes different mechanisms to activate NF-κB, several different therapeutic strategies are needed to address this pathogenetic heterogeneity. Fortunately, a number of drugs that block signaling cascades leading to NF-κB are in early phase clinical trials, several of which are already showing activity in lymphoid malignancies.

Citing Articles

A Transcriptomic Analysis of Laryngeal Dysplasia.

Maffini F, Lepanto D, Chu F, Tagliabue M, Vacirca D, De Berardinis R Int J Mol Sci. 2024; 25(17).

PMID: 39273632 PMC: 11395940. DOI: 10.3390/ijms25179685.


B-cell intrinsic RANK signaling cooperates with TCL1 to induce lineage-dependent B-cell transformation.

Pfeuffer L, Siegert V, Frede J, Rieger L, Trozzo R, de Andrade Kratzig N Blood Cancer J. 2024; 14(1):151.

PMID: 39198400 PMC: 11358282. DOI: 10.1038/s41408-024-01123-6.


A Review on Picrosides Targeting NFκB and its Proteins for Treatment of Breast Cancer.

Soni D, Anjum Z, Raza K, Verma S Cell Biochem Biophys. 2024; 82(2):575-591.

PMID: 38724755 DOI: 10.1007/s12013-024-01281-1.


Positive selection CRISPR screens reveal a druggable pocket in an oligosaccharyltransferase required for inflammatory signaling to NF-κB.

Lampson B, Ramirez A, Baro M, He L, Hegde M, Koduri V Cell. 2024; 187(9):2209-2223.e16.

PMID: 38670073 PMC: 11149550. DOI: 10.1016/j.cell.2024.03.022.


Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review.

Nayak L, Bettegowda C, Scherer F, Galldiks N, Ahluwalia M, Baraniskin A Neuro Oncol. 2024; 26(6):993-1011.

PMID: 38598668 PMC: 11145457. DOI: 10.1093/neuonc/noae032.


References
1.
Emmerich F, Theurich S, Hummel M, Haeffker A, Vry M, Dohner K . Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. J Pathol. 2003; 201(3):413-20. DOI: 10.1002/path.1454. View

2.
Johnson S, Pleiman C, Pao L, Schneringer J, Hippen K, Cambier J . Phosphorylated immunoreceptor signaling motifs (ITAMs) exhibit unique abilities to bind and activate Lyn and Syk tyrosine kinases. J Immunol. 1995; 155(10):4596-603. View

3.
Barth T, Joos S, Menz C, Hasel C, Mechtersheimer G, Parwaresch R . Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood. 2003; 101(9):3681-6. DOI: 10.1182/blood-2002-08-2577. View

4.
Hara H, Wada T, Bakal C, Kozieradzki I, Suzuki S, Suzuki N . The MAGUK family protein CARD11 is essential for lymphocyte activation. Immunity. 2003; 18(6):763-75. DOI: 10.1016/s1074-7613(03)00148-1. View

5.
Mandelbaum J, Bhagat G, Tang H, Mo T, Brahmachary M, Shen Q . BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell. 2010; 18(6):568-79. PMC: 3030476. DOI: 10.1016/j.ccr.2010.10.030. View